Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged>65 or older: week 48 results from a phase 3b, open-label trial

被引：0
|
作者：
Maggiolo, F. [1 ]
Rizzardini, G. [2 ]
Molina, J-M [3 ]
Pulido, F. [4 ]
De Wit, S. [5 ]
Vandekerckhove, L. [6 ]
Berenguer, J. [7 ]
D'Antoni, M. [8 ]
Blair, C. [8 ]
Chuck, S. [8 ]
Piontkowsky, D. [8 ]
Martin, H. [8 ]
McNicholl, I. [8 ]
Haubrich, R. [8 ]
Gallant, J. [8 ]
机构：
[1] ASST Papa Giovanni XXIII, Div Infect Dis, Bergamo, Italy
[2] ASST Fatebenefratelli, Luigi Sacco Hosp, Div Infect Dis, Milan, Italy
[3] St Louis Hosp, Paris, France
[4] Hosp Univ 12 Octubre, Unidad VIH, Madrid, Spain
[5] St Pierre Univ Hosp, Brussels, Belgium
[6] Univ Hosp, Ghent, Belgium
[7] Hosp Gen Univ Gregorio Maranon IiSGM, Madrid, Spain
[8] Gilead Sci, Foster City, CA USA
来源：
HIV MEDICINE | 2019年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
PE9/49
引用
收藏
页码：138 / 138
页数：1
相关论文
共 50 条
  • [1] Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged >65 or older: week 48 results from a phase 3b, open-label trial
    Maggiolo, F.
    Rizzardini, G.
    Molina, J. M.
    Pulido, F.
    DeWit, S.
    Vandekerckhove, L.
    Berenguer, J.
    D'Antoni, M.
    Blair, C.
    Chuck, S.
    Piontkowsky, D.
    Martin, H.
    McNicholl, I.
    Payne, B.
    Gallant, J.
    [J]. HIV MEDICINE, 2020, 21 : 17 - 17
  • [2] Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial
    Franco Maggiolo
    Giuliano Rizzardini
    Jean-Michel Molina
    Federico Pulido
    Stephane De Wit
    Linos Vandekerckhove
    Juan Berenguer
    Michelle L. D’Antoni
    Christiana Blair
    Susan K. Chuck
    David Piontkowsky
    Hal Martin
    Richard Haubrich
    Ian R. McNicholl
    Joel Gallant
    [J]. Infectious Diseases and Therapy, 2021, 10 : 775 - 788
  • [3] Switching to bictegravir/emtricitabine/tenofovir alafenamide in adults aged >65 years or older: Week 72 results from an international, phase IIIb, open-label trial
    Maggiolo, F.
    Rizzardini, G.
    Molina, J.
    Pulido, F.
    De Wit, S.
    Vandekerckhove, L.
    Berenguer, J.
    D'Antoni, M.
    Blair, C.
    Chuck, S.
    Piontkowsky, D.
    Martin, H.
    Haubrich, R.
    McNicholl, I.
    Gallant, J.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 43 - 44
  • [4] Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial
    Maggiolo, Franco
    Rizzardini, Giuliano
    Molina, Jean-Michel
    Pulido, Federico
    De Wit, Stephane
    Vandekerckhove, Linos
    Berenguer, Juan
    D'Antoni, Michelle L.
    Blair, Christiana
    Chuck, Susan K.
    Piontkowsky, David
    Martin, Hal
    Haubrich, Richard
    McNicholl, Ian R.
    Gallant, Joel
    [J]. INFECTIOUS DISEASES AND THERAPY, 2021, 10 (02) : 775 - 788
  • [5] Pooled analysis of 4 international trials of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged > 65 or older demonstrating safety and efficacy: Week 48 Results
    Ramgopal, M.
    Maggiolo, F.
    Ward, D.
    Lebouche, B.
    Rizzardini, G.
    Molina, J. -M.
    Brinson, C.
    Wang, H.
    Gallant, J.
    Collins, S.
    McNicholl, I.
    Martin, H.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 18 - 18
  • [6] Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people ≥65 years of age
    Maggiolo, Franco
    Rizzardini, Giuliano
    Molina, Jean-Michel
    Pulido, Federico
    De Wit, Stephane
    Vandekerckhove, Linos
    Berenguer, Juan
    D'Antoni, Michelle L.
    Blair, Christiana
    Chuck, Susan K.
    Piontkowsky, David
    Martin, Hal
    Haubrich, Richard
    McNicholl, Ian R.
    Gallant, Joel
    [J]. HIV MEDICINE, 2023, 24 (01) : 27 - 36
  • [7] Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study
    Hagins, Debbie
    Kumar, Princy
    Saag, Michael
    Wurapa, Anson K.
    Brar, Indira
    Berger, Daniel
    Osiyemi, Olayemi
    Hileman, Corrilynn O.
    Ramgopal, Moti N.
    McDonald, Cheryl
    Blair, Christiana
    Andreatta, Kristen
    Collins, Sean E.
    Brainard, Diana M.
    Martin, Hal
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2021, 88 (01) : 86 - 95
  • [8] Metabolic effects of switching to tenofovir alafenamide/emtricitabine/bictegravir (B/F/TAF) from tenofovir difumarate (TDF) or tenofovir alafenamide (TAF) sparing regimens: METABIC study
    Busca, C.
    Ortega, D.
    Martin-Carbonero, L.
    Mican, R.
    Ramos, L.
    Valencia, M.
    Montejano, R.
    Montes, M.
    Diaz-Almiron, M.
    Delgado, A.
    Bernardino, J.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 150 - 151
  • [9] Week 48 outcomes from the BRAAVE 2020 study: a randomised switch to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in African American adults with HIV
    Hagins, D.
    Kumar, P.
    Wurapa, A.
    Brar, I.
    Berger, D.
    Osiyemi, O.
    Hileman, C.
    Ramgopal, M.
    McDonald, C.
    Blair, C.
    Andreatta, K.
    Collins, S. E.
    Brainard, D.
    Gohlar, G.
    Martin, H.
    [J]. HIV MEDICINE, 2021, 22 : 33 - 34
  • [10] Switching to a single-tablet regimen bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) from dolutegravir (DTG) plus emtricitabine and either tenofovir alafenamide or tenofovir disoproxil fumarate (F/TAF or F/TDF)
    Sax, P. E.
    Rockstroh, J.
    Luetkemeyer, A.
    Yasdanpanah, Y.
    Ward, D.
    Trottier, B.
    Rieger, A.
    Liu, H.
    Acosta, R.
    Collins, S. E.
    Brainard, D.
    Martin, H.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 : 3 - 4
12345